RGNX
Price
$11.66
Change
+$0.06 (+0.52%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
587.48M
110 days until earnings call
Intraday BUY SELL Signals
VRTX
Price
$434.75
Change
+$0.56 (+0.13%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
110.16B
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGNX vs VRTX

Header iconRGNX vs VRTX Comparison
Open Charts RGNX vs VRTXBanner chart's image
REGENXBIO
Price$11.66
Change+$0.06 (+0.52%)
Volume$4.86K
Capitalization587.48M
Vertex Pharmaceuticals
Price$434.75
Change+$0.56 (+0.13%)
Volume$23.58K
Capitalization110.16B
RGNX vs VRTX Comparison Chart in %
RGNX
Daily Signal:
Gain/Loss:
VRTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RGNX vs. VRTX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and VRTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (RGNX: $11.60 vs. VRTX: $434.19)
Brand notoriety: RGNX and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 92% vs. VRTX: 90%
Market capitalization -- RGNX: $589.25M vs. VRTX: $110.25B
RGNX [@Biotechnology] is valued at $589.25M. VRTX’s [@Biotechnology] market capitalization is $110.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 2 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 2 green, 3 red.
According to our system of comparison, VRTX is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 3 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).

  • RGNX’s TA Score: 3 bullish, 5 bearish.
  • VRTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -0.09% price change this week, while VRTX (@Biotechnology) price change was +4.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

VRTX is expected to report earnings on Feb 04, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($110B) has a higher market cap than RGNX($587M). RGNX YTD gains are higher at: 50.065 vs. VRTX (7.820). VRTX has higher annual earnings (EBITDA): 4.59B vs. RGNX (-129.93M). VRTX has more cash in the bank: 6.38B vs. RGNX (323M). RGNX has less debt than VRTX: RGNX (77.7M) vs VRTX (1.53B). VRTX has higher revenues than RGNX: VRTX (11.4B) vs RGNX (156M).
RGNXVRTXRGNX / VRTX
Capitalization587M110B1%
EBITDA-129.93M4.59B-3%
Gain YTD50.0657.820640%
P/E RatioN/A30.56-
Revenue156M11.4B1%
Total Cash323M6.38B5%
Total Debt77.7M1.53B5%
FUNDAMENTALS RATINGS
RGNX vs VRTX: Fundamental Ratings
RGNX
VRTX
OUTLOOK RATING
1..100
7016
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10033
SMR RATING
1..100
9741
PRICE GROWTH RATING
1..100
4353
P/E GROWTH RATING
1..100
1728
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (72) in the Biotechnology industry is in the same range as VRTX (79). This means that RGNX’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (33) in the Biotechnology industry is significantly better than the same rating for RGNX (100). This means that VRTX’s stock grew significantly faster than RGNX’s over the last 12 months.

VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for RGNX (97). This means that VRTX’s stock grew somewhat faster than RGNX’s over the last 12 months.

RGNX's Price Growth Rating (43) in the Biotechnology industry is in the same range as VRTX (53). This means that RGNX’s stock grew similarly to VRTX’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is in the same range as VRTX (28). This means that RGNX’s stock grew similarly to VRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXVRTX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
46%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
58%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
59%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 7 days ago
40%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signal:
Gain/Loss:
VRTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCMAX32.121.02
+3.28%
OCM Gold Atlas
ARIFX13.340.07
+0.53%
Aristotle International Eq I
HCAYX60.980.02
+0.03%
Hartford Capital Appreciation Y
GSCLX34.15-0.06
-0.18%
Goldman Sachs Large Cap Gr Insghts Svc
CUSRX13.10-0.08
-0.61%
Cullen Small Cap Value Retail

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.43%
SYRE - RGNX
56%
Loosely correlated
+0.34%
DNLI - RGNX
55%
Loosely correlated
-0.34%
BEAM - RGNX
54%
Loosely correlated
-2.71%
VYGR - RGNX
54%
Loosely correlated
-0.23%
MGNX - RGNX
53%
Loosely correlated
-3.29%
More

VRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with NEVPF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRTX
1D Price
Change %
VRTX100%
+1.16%
NEVPF - VRTX
47%
Loosely correlated
N/A
SNDX - VRTX
41%
Loosely correlated
-5.30%
IDYA - VRTX
35%
Loosely correlated
-0.19%
KRYS - VRTX
33%
Poorly correlated
+0.01%
RGNX - VRTX
32%
Poorly correlated
+0.43%
More